Juvenescence US Corp. - 14 Mar 2023 Form 3 Insider Report for AgeX Therapeutics, Inc. (SER)

Role
Director, 10%+ Owner
Signature
/s/ David Gill, Vice President and Treasurer
Issuer symbol
SER
Transactions as of
14 Mar 2023
Net transactions value
$0
Form type
3
Filing time
22 Mar 2023, 16:19:25 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AGE Common Stock 16,447,500 14 Mar 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired pursuant to a transfer of securities from the reporting person's sole stockholder, Juvenescence Limited.

Remarks:

Director by deputization